1 / 17

Discontinuation of second generation tyrosine kinase inhibitors

Discontinuation of second generation tyrosine kinase inhibitors. Dr Delphine Rea Service des Maladies du Sang Hôpital Saint-Louis Paris, France Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques). CML and MPDs UK national meeting Newcastle, March 1 st , 2013.

tyme
Télécharger la présentation

Discontinuation of second generation tyrosine kinase inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Discontinuation of second generation tyrosine kinase inhibitors Dr Delphine Rea Service des Maladies du Sang Hôpital Saint-Louis Paris, France Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques) CML and MPDs UK national meeting Newcastle, March 1st, 2013

  2. Current goals of TKI therapy « Induction » phase « Lifelong maintenance » CP-CML at Diagnosis Near-normal life expectancy PFS EFS CHR, Minor CyR PCyR CCyR MMR Leukemic burden Stable or improving MMR > M18 M3 M6 M12 M18 Treatment change upon lack or loss of an optimal response, progression or unacceptable side effects Time on TKI therapy Baccaraniet al. JCO 2009; 27: 6041-6051 Björkholm et al. JCO 2011: 2514-2420 Gambacorti-Passerini et al. JNCI 2011; 103: 553-561

  3. Evidence that TKIs may not be curative • Primitive CD34+CD38- BCR-ABL+ cells are insensitive to imatinib-, dasatinib-, nilotinib- and bosutinib-induced cell death in vitro1-4 • CD34+CD38- BCR-ABL+ cells escape from TKI-induced cell death is independent from BCR-ABL in vitro5 • CD34+CD38- BCR-ABL+ residual cells in optimal responders to imatinib survive independently from BCR-ABL and possess in vivo repopulating capacities in mice6 1Graham et al. Blood 2002; 99: 319-325 2Copland et al. Blood 2006; 107: 4532-4539 3Jorgensen et al. Blood 2007; 109: 4016-4019 4Konig et al. Blood 2008; 111: 2329-2338 5Corbin et al. JCI 2011; 121: 396-406 6Hamilton et al. Blood 2012; 119: 1501-1510

  4. Median BCR-ABL (IS) transcript levels over 84 months in the IRIS trial 0.003% 0.004% Hughes et al. Blood 2010; 116: 3758-3765

  5. STIM: Stopping imatinib is feasible CP-CML Imatinib≥3 years Undetectable BCR-ABL≥2 years 1.0 Survival without molecular relapse: 39% (95% CI: 29-48) at 24 and 36 months 0.9 0.8 0.7 0.6 Survival without molecular relapse 0.5 0.4 0.3 0.2 Molecular relapses: n=61 0.1 Median follow-up: 34 months (9-50) 0.0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 Months since discontinuation of imatinib Undetectable BCR-ABL: at least 50 000 copies of the ABL control gene Molecular relapse:defined by 2 positive RQ-PCR results over 1 month showing a significant rise in BCR-ABL transcripts; triggers imatinib resumption. Mahon et al. Blood (ASH) 2011; 118: Abstract 603

  6. Factors potentially associated with outcome 1Mahon et al. Blood (ASH) 2011; 118: Abstract 603 2Ross et al. Haematologica 2012; abstract 0189. 3Takahashi et al. Haematologica 2012; 97: 903-906 4Yhim et al. Leukemia Research 2012; 36: 689-693

  7. Rationale for 2G-TKI discontinuation • Dasatinib and nilotinib display increased potency in vitro against BCR-ABL compared with imatinib1 • Dasatinib and nilotinib are efficient salvage therapies in patients with intolerance or resistance to imatinib2,3 • Frontline dasatinib and nilotinib induce higher rates of deep molecular responses than imatinib4,5 • Case reports on dasatinib cessation in 4 patients with imatinib-resistant CML with very low or undetectable BCR-ABL transcripts6,7 4Saglio et al. N Engl J Med 2010; 362: 2251-2259 5Kantarjian et al. N Engl J Med 2010; 362: 2260-2270 6Rea et al. Leukemia 2009; 23: 1158-1159 7Ross et al. Haematologica 2011; 96: 1720-1722 1O’Hare et al. Cancer Res 2005; 65: 4500-4505 2Shah et al. J ClinOncol 2008; 26; 3204-3212 3Kantarjian et al. Blood 2007; 110: 3540-3546

  8. STOP 2G-TKI: study design Primary endpoint: survival without loss of MMR Molecular relapse: loss of MMR Loss of MMR triggered treatment resumption CP-CML TKI therapy ≥ 3 years 2G-TKI frontline or after imatinib intolerance or resistance D1 M12 M24 M36 M48 M60 Undetectable BCR-ABL* ≥ 24 months STOP 2G-TKI Year 1 Year 2 Year 3-5 RQ-PCR monthly RQ-PCR Every 2-3 months RQ-PCR Every 3-6 months *Molecular monitoring performed in local laboratories filling international standardization requirements. *20 000 copies of ABL at least.

  9. Baseline characteristics *ELN 2006 definition Rea et al. Blood (ASH) 2012; 120: Abstract 916

  10. Survival without MMR loss Median follow-up was 17 months (7-38) 16/39 patients lost MMR Median time to MMR loss was 3 months (1-25) STOP 2G-TKI 100 Month 12: 61.1% (95% CI: 45.6-76.6) 80 60 Survival without MMR loss % 40 20 0 0 6 12 18 24 30 36 42 KM analysis Months since 2G-TKI discontinuation Rea et al. Blood (ASH) 2012; 120: Abstract 916

  11. STOP 2G-TKI Outcome after MMR loss • Median BCR-ABL transcript level at MMR loss: • 0.35% IS (0.12-1.95) • TKI therapy resumption in 15/16 patients • Median time between MMR loss and therapy resumption: 1 month (0-4) • Same 2G-TKI used prior to discontinuation in all patients but 1 • No loss of CHR or progression to AP/BP • With a median follow-up of 7 (1-35) months after therapy resumption: • MMR regained in14 patients, median time to MMR 2 (1-6) months • Undetectable BCR-ABL transcripts in 14 patients after a median time of 4 months (3-10) Rea et al. Blood (ASH) 2012; 120: Abstract 916

  12. STOP 2G-TKI Responsiveness to 2G-TKI upon therapy resumption: patient case STOP DASATINIB 10 DASATINIB RESUMPTION 1 MMR 0.1 BCR-ABL/ABL % IS 0.01 MR4.5 0.001 0.0001 0 6 12 18 24 30 36 42 48 54 60 66 Detectable BCR-ABL Months since dasatinib-induced undetectable BCR-ABL transcripts Undetectable BCR-ABL with at least 32000 copies of ABL Dr D Rea, Hôpital Saint-Louis, Paris

  13. STOP 2G-TKI Factors associated with outcome KM analysis, two-tailed logrank test Rea et al. Blood (ASH) 2012; 120: Abstract 916

  14. STOP 2G-TKI BCR-ABL transcripts in patients remaining in MMR

  15. BCR-ABL+ LSC Different outcomes of persistent LSC CML disease relapse Mat Mat Self renewal Mat Ph+ LSC- driven hematopoiesis STOP TKI Pre Mat Pre Pro Pre Pro Deep and sustained Molecular response TKI + Inhibited Ph+ LSC- driven hematopoiesis No CML disease relapse Survival STOP TKI Why ? CML-related factors? Therapy-related factors? Host-related factors?

  16. Conclusions • Discontinuation of 2G-TKI in patients with deep and sustained molecular responses is possible without jeopardizing short-term outcome, under strict monitoring conditions. • TKI discontinuation may not be a realistic goal for all patients but the increasing use of 2G-TKI may broaden access to treatment discontinuation attempts. • Patients who successfully stop TKI may not be definitively cured, likely because of LSC persistence. • Unknown long-term risk of relapse, acquired resistance and progression to AP/BP after TKI discontinuation. • Targeting residual LSC with specific compounds may offer a chance for a definitive cure.

More Related